NANJING, China, November 22, 2024 -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global intellectual property rights for the treatment of neuroendocrine cancer

Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody

NANJING, China, November 1st, 2024--Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is independently developed by Leads Biolabs with global intellectual property r

NANJING, China, October 9, 2024--Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently develop

NANJING, China, September 27, 2024— Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the most recent clinical research findings of LBL-024, an anti-PD-L1/4-1BB bispecific antibody, and LBL-007, an anti-LAG-3 antibody, were showcased in an

The 2024 Chinese Society of Clinical Oncology（CSCO）Annual Meeting will be held in Xiamen from September 25th to September 29th. As the most authoritative and influential annual event in the field of oncology in China, CSCO consistently propels the advancement and development of oncology disciplines

Nanjing, China (June 17, 2024) At the recent European League Against Rheumatism (EULAR) Congress in Vienna, Austria, Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) delivered an oral presentation on its highly innovative therapeutic candidate LBL-047. LBL-047 is a first-in-class, long-acting TACI/BD

Nanjing, China, June 2 (Chicago) and June 3 (Beijing), 2024 - The annual meeting of the American Society of Clinical Oncology (ASCO) commenced on May 31st, Showcasing groundbreaking cancer research from around the world. According to official information, over 7,000 abstracts were submitted this yea

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024. As the largest and most academically prestigious international oncology conference in the world, the ASCO Annual Meeting gathers the latest and most cutting-edge research finding

NANJING, China, April 30, 2024--Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to conduct the single-a